amlodipine has been researched along with Diabetic Glomerulosclerosis in 71 studies
Amlodipine: A long-acting dihydropyridine calcium channel blocker. It is effective in the treatment of ANGINA PECTORIS and HYPERTENSION.
amlodipine : A fully substituted dialkyl 1,4-dihydropyridine-3,5-dicarboxylate derivative, which is used for the treatment of hypertension, chronic stable angina and confirmed or suspected vasospastic angina.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Inhibition of the rennin-angiotensin system (RAS) could reduce insulin resistance in patients with hypertension and diabetic kidney disease (DKD), but whether the effect of losartan on insulin resistance is associated with reduction of oxidative stress and enhancement of insulin signaling transduction has not been fully elucidated." | 9.20 | Losartan reduces insulin resistance by inhibiting oxidative stress and enhancing insulin signaling transduction. ( Fu, SK; Gu, HF; Hu, C; Jin, HM; Liu, XL; Pan, LH; Pan, Y; Qiao, QY; Zhou, DC, 2015) |
| " In this study, we conducted an open-label and randomized trial to compare the effects of benidipine with those of amlodipine on blood pressure (BP), albuminuria and aldosterone concentration in hypertensive patients with mild-to-moderate stage chronic kidney disease (CKD)." | 9.15 | Benidipine reduces albuminuria and plasma aldosterone in mild-to-moderate stage chronic kidney disease with albuminuria. ( Abe, M; Fujita, T; Maruyama, N; Maruyama, T; Matsumoto, K; Matsumoto, S; Okada, K; Soma, M, 2011) |
| "Forty type 2 diabetic patients with hypertension and nephropathy receiving angiotensin receptor II blockers were enrolled and randomly divided into two groups: the efonidipine group was administered efonidipine hydrochloride ethanolate 40 mg/day and the amlodipine group was admin-istered amlodipine besilate 5 mg/day for 12 months." | 9.14 | Protective effects of efonidipine, a T- and L-type calcium channel blocker, on renal function and arterial stiffness in type 2 diabetic patients with hypertension and nephropathy. ( Ban, N; Endo, K; Kawana, H; Miyashita, Y; Nagayama, D; Ohhira, M; Oyama, T; Saiki, A; Sasaki, H; Shirai, K; Yamaguchi, T, 2009) |
| "In addition to reducing urinary protein excretion, losartan at 100 mg daily increases insulin sensitivity and improves glucose homeostasis in subjects with type 2 diabetic nephropathy." | 9.12 | Angiotensin type-1 receptor blockade with losartan increases insulin sensitivity and improves glucose homeostasis in subjects with type 2 diabetes and nephropathy. ( Jin, HM; Pan, Y, 2007) |
| " The MicroAlbuminuria Reduction With VALsartan (MARVAL) study was designed to evaluate the BP-independent effect of valsartan on UAER in type 2 diabetic patients with microalbuminuria." | 9.10 | Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect. ( Viberti, G; Wheeldon, NM, 2002) |
| "In the present quantitative overview of outcome trials, we investigated the efficacy of amlodipine or angiotensin receptor blockers in the prevention of stroke and myocardial infarction in patients with hypertension, coronary artery disease, or diabetic nephropathy." | 8.84 | Prevention of stroke and myocardial infarction by amlodipine and Angiotensin receptor blockers: a quantitative overview. ( Franklin, SS; Li, Y; Safar, M; Wang, JG, 2007) |
| " The authors hypothesized that reduction in aldosterone production in diabetes by amlodipine or aliskiren improves diabetic kidney disease by attenuating renal oxidative stress and fibrosis." | 7.79 | Reduction of aldosterone production improves renal oxidative stress and fibrosis in diabetic rats. ( Matavelli, LC; Siragy, HM, 2013) |
| "The present study assessed the cost effectiveness of irbesartan, an angiotensin II receptor antagonist, and amlodipine, a calcium channel blocker, in the treatment of Canadian patients with diabetic nephropathy and hypertension." | 7.72 | Economic evaluation of the use of irbesartan and amlodipine in the treatment of diabetic nephropathy in patients with hypertension in Canada. ( Coyle, D; Rodby, RA, 2004) |
| " Furthermore, the depletion in glomerular nephrin expression in diabetic animals was only abrogated by valsartan treatment, the therapy which was most effective at retarding the development of albuminuria in this model." | 7.72 | Disparate effects of angiotensin II antagonists and calcium channel blockers on albuminuria in experimental diabetes and hypertension: potential role of nephrin. ( Allen, TJ; Cao, Z; Cooper, ME; Davis, BJ; de Gasparo, M; Kawachi, H, 2003) |
| "Eighty subjects with type 2 diabetic nephropathy were randomly divided into two groups: losarten group (n = 41) and amlodipine group (n = 39)." | 6.74 | Adiponectin is positively associated with insulin resistance in subjects with type 2 diabetic nephropathy and effects of angiotensin II type 1 receptor blocker losartan. ( Guo, LL; Jin, HM; Pan, Y, 2009) |
| "Inhibition of the rennin-angiotensin system (RAS) could reduce insulin resistance in patients with hypertension and diabetic kidney disease (DKD), but whether the effect of losartan on insulin resistance is associated with reduction of oxidative stress and enhancement of insulin signaling transduction has not been fully elucidated." | 5.20 | Losartan reduces insulin resistance by inhibiting oxidative stress and enhancing insulin signaling transduction. ( Fu, SK; Gu, HF; Hu, C; Jin, HM; Liu, XL; Pan, LH; Pan, Y; Qiao, QY; Zhou, DC, 2015) |
| "The aim of this study was to compare the effects of a dihidropiridin calcium channel blocker amlodipin and a non-dihidropiridin calcium channel blocker verapamil on nephropathy and serum pigment epithelium-derived factor (PEDF) levels of type 2 diabetic patients with hypertension." | 5.20 | The effects of calcium channel blockers on nephropathy and pigment epithelium-derived factor in the treatment of hypertensive patients with type 2 diabetes mellitus. ( Çelik, H; Korkmaz, H; Oğuz, E; Sabuncu, T; Tabur, S, 2015) |
| " Intact FGF-23, the eGFR, proteinuria and the endothelium-dependent flow-mediated (FMD) response to ischemia and other parameters were measured at baseline and after 12-weeks of treatment with ramipril (n = 68) or amlodipine (n = 32)." | 5.19 | Ramipril lowers plasma FGF-23 in patients with diabetic nephropathy. ( Cetinkaya, H; Eyileten, T; Gok, M; Karaman, M; Kurt, YG; Mallamaci, F; Oguz, Y; Saglam, M; Sonmez, A; Unal, HU; Vural, A; Yilmaz, MI; Zoccali, C, 2014) |
| "Cilnidipine did not offer greater renoprotection than amlodipine in RAS inhibitor-treated hypertensive patients with type 2 diabetes and microalbuminuria." | 5.17 | Comparison of the antialbuminuric effects of L-/N-type and L-type calcium channel blockers in hypertensive patients with diabetes and microalbuminuria: the study of assessment for kidney function by urinary microalbumin in randomized (SAKURA) trial. ( Ando, K; Fujita, T; Kosugi, S; Matsuoka, H; Nakao, K; Sato, T; Tanaka, S; Ueshima, K, 2013) |
| " In this study, we conducted an open-label and randomized trial to compare the effects of benidipine with those of amlodipine on blood pressure (BP), albuminuria and aldosterone concentration in hypertensive patients with mild-to-moderate stage chronic kidney disease (CKD)." | 5.15 | Benidipine reduces albuminuria and plasma aldosterone in mild-to-moderate stage chronic kidney disease with albuminuria. ( Abe, M; Fujita, T; Maruyama, N; Maruyama, T; Matsumoto, K; Matsumoto, S; Okada, K; Soma, M, 2011) |
| "5-5 mg/day) in olmesartan-treated hypertensive (blood pressure 130-180/80-110 mmHg) patients with type 2 diabetes (fasting blood sugar ≥126 mg/dL or treatment with antidiabetic agents) and albuminuria (urinary albumin/creatinine ratio ≥30 mg/g)." | 5.15 | Design and rationale of Japanese evaluation between Formula of Azelnidipine and amlodipine add on olmesartan to Get antialbuminuric effect study (J-FLAG) : evaluation of the antialbuminuric effects between calcium channel blocker with sympatholytic action ( Ando, K; Fujita, T; Haneda, M; Ito, S; Kashihara, N; Kishimoto, J; Nangaku, M; Node, K; Shimosawa, T, 2011) |
| " To elucidate our hypothesis, we designed a multi-center, open-labeled, randomized trial to compare the antialbuminuric effect between cilnidipine and amlodipine in RAS inhibitor-treated hypertensive (blood pressure [BP]: 130-180/80-110 mmHg) patients with type 2 diabetes and microalbuminuria (urinary albumin/creatinine [Cr] ratio: 30-300 mg/g)." | 5.15 | Design and rationale of the study of assessment for kidney function by urinary microalbumin in randomized (SAKURA) trial. ( Ando, K; Babazono, T; Fujita, T; Kario, K; Matsuoka, H; Nakao, K; Tanaka, S; Ueshima, K, 2011) |
| "Forty type 2 diabetic patients with hypertension and nephropathy receiving angiotensin receptor II blockers were enrolled and randomly divided into two groups: the efonidipine group was administered efonidipine hydrochloride ethanolate 40 mg/day and the amlodipine group was admin-istered amlodipine besilate 5 mg/day for 12 months." | 5.14 | Protective effects of efonidipine, a T- and L-type calcium channel blocker, on renal function and arterial stiffness in type 2 diabetic patients with hypertension and nephropathy. ( Ban, N; Endo, K; Kawana, H; Miyashita, Y; Nagayama, D; Ohhira, M; Oyama, T; Saiki, A; Sasaki, H; Shirai, K; Yamaguchi, T, 2009) |
| " We hypothesized that a trandolapril/verapamil SR (T/V) fixed-dose combination (FDC) was superior to a benazepril/amlodipine (B/A) FDC for reducing albuminuria in 304 hypertensive diabetic nephropathy patients when treated for 36 weeks." | 5.13 | Effects of calcium channel blockers on proteinuria in patients with diabetic nephropathy. ( Bacher, P; Champion, A; Fakouhi, K; Tian, M; Toto, RD, 2008) |
| "In addition to reducing urinary protein excretion, losartan at 100 mg daily increases insulin sensitivity and improves glucose homeostasis in subjects with type 2 diabetic nephropathy." | 5.12 | Angiotensin type-1 receptor blockade with losartan increases insulin sensitivity and improves glucose homeostasis in subjects with type 2 diabetes and nephropathy. ( Jin, HM; Pan, Y, 2007) |
| "Associations between baseline proteinuria and proteinuria reduction by either irbesartan, amlodipine, or control for similar decrements in blood pressure and the cumulative incidence of renal end points were examined using the Kaplan-Meier method in patients enrolled in the Irbesartan Diabetic Nephropathy Trial." | 5.11 | Proteinuria reduction and progression to renal failure in patients with type 2 diabetes mellitus and overt nephropathy. ( Atkins, RC; Braden, G; Briganti, EM; Champion de Crespigny, PJ; DeFerrari, G; Drury, P; Hunsicker, LG; Lewis, EJ; Lewis, JB; Locatelli, F; Wiegmann, TB, 2005) |
| " A new clinical trial, GUARD (Gauging Albuminuria Reduction With Lotrel in Diabetic Patients With Hypertension), is designed to compare the change in urinary albumin to creatinine ratio after 1 year of initial treatment with either amlodipine besylate/benazepril HCl or benazepril HCl/hydrochlorothiazide." | 5.11 | Rationale and design of a study comparing two fixed-dose combination regimens to reduce albuminuria in patients with type II diabetes and hypertension. ( Bakris, GL; McCullough, PA; Toto, RD, 2005) |
| " Using treatment-specific probabilities derived from the Irbesartan in Diabetic Nephropathy Trial (IDNT), the cost effectiveness of treating patients with hypertension, type II diabetes and nephropathy with irbesartan, amlodipine or control was calculated using a Markov model." | 5.11 | An economic evaluation of the Irbesartan in Diabetic Nephropathy Trial (IDNT) in a UK setting. ( Annemans, L; Bilous, RW; Lamotte, M; Palmer, AJ; Rodby, RA; Roze, S, 2004) |
| " The MicroAlbuminuria Reduction With VALsartan (MARVAL) study was designed to evaluate the BP-independent effect of valsartan on UAER in type 2 diabetic patients with microalbuminuria." | 5.10 | Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect. ( Viberti, G; Wheeldon, NM, 2002) |
| "In the present quantitative overview of outcome trials, we investigated the efficacy of amlodipine or angiotensin receptor blockers in the prevention of stroke and myocardial infarction in patients with hypertension, coronary artery disease, or diabetic nephropathy." | 4.84 | Prevention of stroke and myocardial infarction by amlodipine and Angiotensin receptor blockers: a quantitative overview. ( Franklin, SS; Li, Y; Safar, M; Wang, JG, 2007) |
| "Currently, AIIAs such as losartan represent the only evidence-based treatment strategy for patients with type 2 DM and proteinuria." | 4.82 | Losartan and other angiotensin II antagonists for nephropathy in type 2 diabetes mellitus: a review of the clinical trial evidence. ( Ruilope, LM; Segura, J, 2003) |
| "SEVERAL MECHANISMS: The progression in renal failure first implies hemodynamic mechanisms and among which angiotensin II has a central role, but also an increase in proteinuria and the induction of many inflammatory and mitogenic mediators that enhance fibrosis (TGF-beta), an effect stimulating the thrombotic mechanism." | 4.81 | [The effect of angiotensin-converting enzyme inhibitors on the progression of chronic renal failure]. ( Bernadet-Monrozies, P; Durand, D; Kamar, N; Rostaing, L, 2002) |
| "The results of this study suggested that the L/N-type CCB, cilnidipine, had additive antihypertensive and proteinuria-lowering effects when administered in combination with an ARB, even in type-1 diabetic rats, and that the L-type CCB, amlodipine, did not." | 3.79 | Additive effects of cilnidipine and angiotensin II receptor blocker in preventing the progression of diabetic nephropathy in diabetic spontaneously hypertensive rats. ( Aritomi, S; Konda, T; Niinuma, K; Nitta, K; Ogawa, T, 2013) |
| " The authors hypothesized that reduction in aldosterone production in diabetes by amlodipine or aliskiren improves diabetic kidney disease by attenuating renal oxidative stress and fibrosis." | 3.79 | Reduction of aldosterone production improves renal oxidative stress and fibrosis in diabetic rats. ( Matavelli, LC; Siragy, HM, 2013) |
| "Diabetic nephropathy is the most common cause of end-stage renal disease (ESRD) in the United States, and accounts for 35% of all the patients with ESRD entering a dialysis program; 63% of patients with diabetic nephropathy have type II diabetes mellitus." | 3.78 | Renoprotection and renin-angiotensin system blockade in diabetes mellitus. ( Ruilope, LM, 1997) |
| "The irbesartan in Diabetic Nephropathy Trial (IDNT) demonstrated that treatment of patients with type 2 diabetes, hypertension and nephropathy with irbesartan resulted in a 20% relative reduction of the composite endpoint of doubling serum creatinine, end-stage renal disease or death as compared with amlodipine and placebo (antihypertensive standard therapy)." | 3.73 | [Health economic consequences of the use of irbesartan in patients with type 2 diabetes, hypertension and nephropathy in Switzerland]. ( Burnier, M; Frei, A; Hess, B; Palmer, AJ, 2006) |
| "Three treatments for hypertension patients with type 2 diabetes mellitus and nephropathy were assessed: (1) irbesartan, (2) amlodipine, and (3) placebo." | 3.72 | The cost-effectiveness of irbesartan in the treatment of hypertensive patients with type 2 diabetic nephropathy. ( Annemans, L; Borenstein, J; Chen, RS; Chiou, CF; Lewis, EJ; Palmer, AJ; Rodby, RA; Roze, S; Sengupta, N; Simon, TA; Smitten, A, 2003) |
| "Treating patients with hypertension, type 2 diabetes and nephropathy using irbesartan lowers the cumulative incidence of ESRD and is cost-saving compared to amlodipine or control." | 3.72 | [Health economic consequences of the use of irbesartan in patients in Germany with type 2 diabetes, nephropathy and hypertension]. ( Annemans, L; Lamotte, M; Palmer, AJ; Ritz, E; Rodby, RA; Roze, S, 2004) |
| " Furthermore, the depletion in glomerular nephrin expression in diabetic animals was only abrogated by valsartan treatment, the therapy which was most effective at retarding the development of albuminuria in this model." | 3.72 | Disparate effects of angiotensin II antagonists and calcium channel blockers on albuminuria in experimental diabetes and hypertension: potential role of nephrin. ( Allen, TJ; Cao, Z; Cooper, ME; Davis, BJ; de Gasparo, M; Kawachi, H, 2003) |
| "The present study assessed the cost effectiveness of irbesartan, an angiotensin II receptor antagonist, and amlodipine, a calcium channel blocker, in the treatment of Canadian patients with diabetic nephropathy and hypertension." | 3.72 | Economic evaluation of the use of irbesartan and amlodipine in the treatment of diabetic nephropathy in patients with hypertension in Canada. ( Coyle, D; Rodby, RA, 2004) |
| "However, the effects of BDNF on diabetic nephropathy are unknown." | 2.80 | Assessment of glomerular filtration rate based on alterations of serum brain-derived neurotrophic factor in type 2 diabetic subjects treated with amlodipine/benazepril or valsartan/hydrochlorothiazide. ( Chen, JF; Hung, YJ; Lee, IT; Lee, WJ; Sheu, WH; Wang, CY, 2015) |
| "Seventy-six patients with type 2 diabetes and DKD (all with albuminuria and serum creatinine <1." | 2.78 | Effect of renin-angiotensin system blockade on soluble Klotho in patients with type 2 diabetes, systolic hypertension, and albuminuria. ( Gnudi, L; Hill, B; Karalliedde, J; Maltese, G; Viberti, G, 2013) |
| "Eighty subjects with type 2 diabetic nephropathy were randomly divided into two groups: losarten group (n = 41) and amlodipine group (n = 39)." | 2.74 | Adiponectin is positively associated with insulin resistance in subjects with type 2 diabetic nephropathy and effects of angiotensin II type 1 receptor blocker losartan. ( Guo, LL; Jin, HM; Pan, Y, 2009) |
| "Amlodipine and ramipril were added to their previous antihypertensive treatment for 12 weeks." | 2.72 | Urinary TGF-beta1 reduction related to a decrease of systolic blood pressure in patients with type 2 diabetes and clinical diabetic nephropathy. ( Bertoluci, MC; Oliveira, FR; Schmid, H; Schmidt, A; Thomazelli, FC; Uebel, D, 2006) |
| "All participants had baseline diabetic nephropathy, overt proteinuria, and hypertension and were recruited between 1996 and 1999." | 2.71 | Total plasma homocysteine and arteriosclerotic outcomes in type 2 diabetes with nephropathy. ( Bostom, AG; Friedman, AN; Hunsicker, LG; Selhub, J, 2005) |
| "Twenty-eight patients who had type 1 diabetes and known diabetic renal disease and had a persistently elevated albumin creatinine ratio (ACR) > 10 mg/mmol despite office BP recordings < or = 140/80 mmHg on maximal recommended dose of the ACEI lisinopril were studied." | 2.71 | Targeting albumin excretion rate in the treatment of the hypertensive diabetic patient with renal disease. ( Bilous, R; Karalliedde, J; Krimholtz, MJ; Thomas, S; Viberti, G, 2005) |
| "1715 adults with type 2 diabetic nephropathy and hypertension; serum creatinine levels of 89 micromol/L (1." | 2.71 | Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy. ( Berl, T; Drury, PL; Esmatjes, E; Goldhaber, SZ; Hricik, D; Hunsicker, LG; Lewis, EJ; Lewis, JB; Locatelli, F; Parikh, CR; Pfeffer, MA; Porush, JG; Raz, I; Rouleau, JL; Vanhille, P; Wiegmann, TB; Wolfe, BM, 2003) |
| "Diabetic nephropathy is the most common cause of end-stage renal disease in the developed world." | 2.69 | The Irbesartan type II diabetic nephropathy trial: study design and baseline patient characteristics. For the Collaborative Study Group. ( Anzalone, DA; Atkins, RC; Clarke, WR; Hunsicker, LG; Lewis, EJ; Ritz, E; Rodby, RA; Rohde, RD, 2000) |
| "Of the hypertensive NIDDM patients attending the outpatient's clinic of the internal medicine departments of the University of Padova and Sassari, 44 participated in the present study." | 2.68 | Effects of cilazapril and amlodipine on kidney function in hypertensive NIDDM patients. ( Brocco, E; Carraro, A; Cernigoi, AM; Fioretto, P; Fresu, P; Frigato, F; Maioli, M; Muollo, B; Nosadini, R; Tonolo, G; Velussi, M; Zolli, M, 1996) |
| "Amlodipine is a classical drug with varied properties extending from control of blood pressure to as an antianginal and anti atherosclerotic agent." | 2.58 | Amlodipine in the Era of New Generation Calcium Channel Blockers. ( Kashyap, R; Langote, A; Tiwaskar, M; Toppo, A, 2018) |
| "Patients with type 2 diabetes and diabetic nephropathy have a dramatically increased cardiovascular risk." | 2.42 | Treatment of diabetic nephropathy with angiotensin II receptor antagonist. ( Lewis, EJ; Lewis, JB, 2003) |
| " Therefore, the results of valsartan and amlodipine tablets combined with alpha-lipoic acid on total antioxidant capacity (T-AOC) need to be investigated." | 1.91 | Effects of Valsartan and Amlodipine Tablets Combined with α-Lipoic Acid on T-AOC, IL-6 and β2-MG Levels in Patients with Diabetic Nephropathy. ( Su, F; Xia, Q, 2023) |
| "The Irbesartan Diabetic Nephropathy Trial (IDNT) demonstrated that irbesartan significantly slowed established Type 2 diabetic nephropathy progression." | 1.38 | Irbesartan delays progression of nephropathy as measured by estimated glomerular filtration rate: post hoc analysis of the Irbesartan Diabetic Nephropathy Trial. ( Bain, SC; Bilous, RW; Evans, M; Hogan, S, 2012) |
| "Ramipril treatment was associated with a significantly lower risk of DM in African Americans with hypertensive kidney disease than amlodipine or metoprolol treatment." | 1.33 | Differing effects of antihypertensive drugs on the incidence of diabetes mellitus among patients with hypertensive kidney disease. ( Agodoa, LY; Appel, LJ; Cheek, D; Contreras, G; Gassman, J; Lash, JP; Miller, ER; Randall, OS; Thornley-Brown, D; Wang, X; Wright, JT, 2006) |
| "Diabetic nephropathy is associated with increased albuminuria and accumulation of extracellular matrix proteins within the kidney." | 1.32 | Calcium channel blockers, either amlodipine or mibefradil, ameliorate renal injury in experimental diabetes. ( Allen, TJ; Cao, Z; Cooper, ME; Ma, G, 2004) |
| "To investigate the effects of the mixed endothelin receptor antagonist, bosentan, combined with the long-acting calcium channel blocker, amlodipine, compared to the angiotensin-converting enzyme inhibitor, cilazapril, on the progressive renal injury in spontaneous hypertensive rats (SHR) with diabetes." | 1.31 | Endothelin receptor antagonist combined with a calcium channel blocker attenuates renal injury in spontaneous hypertensive rats with diabetes. ( Chen, J; Gu, Y; Lin, F; Lin, S; Ma, J; Yang, H; Zhu, W, 2002) |
| "Imidapril treatment significantly decreased urinary albumin excretions and improved glomerulosclerosis of OLETF rats, while amlodipine failed to improve nephropathy of OLETF rats despite lowering of blood pressure." | 1.31 | Role of intrarenal angiotensin-converting enzyme in nephropathy of type II diabetic rats. ( Iwao, H; Kim, S; Taniguchi, M; Zhan, Y, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (2.82) | 18.2507 |
| 2000's | 46 (64.79) | 29.6817 |
| 2010's | 22 (30.99) | 24.3611 |
| 2020's | 1 (1.41) | 2.80 |
| Authors | Studies |
|---|---|
| Su, F | 1 |
| Xia, Q | 1 |
| Tiwaskar, M | 1 |
| Langote, A | 1 |
| Kashyap, R | 1 |
| Toppo, A | 1 |
| Jeon, SY | 1 |
| Lee, NR | 1 |
| Yim, CY | 1 |
| Karalliedde, J | 2 |
| Maltese, G | 1 |
| Hill, B | 1 |
| Viberti, G | 3 |
| Gnudi, L | 1 |
| Ando, K | 3 |
| Ueshima, K | 2 |
| Tanaka, S | 2 |
| Kosugi, S | 1 |
| Sato, T | 1 |
| Matsuoka, H | 2 |
| Nakao, K | 2 |
| Fujita, T | 5 |
| Tabur, S | 1 |
| Oğuz, E | 1 |
| Sabuncu, T | 1 |
| Korkmaz, H | 1 |
| Çelik, H | 1 |
| Uchida, S | 1 |
| Takahashi, M | 1 |
| Sugawara, M | 1 |
| Saito, T | 1 |
| Nakai, K | 1 |
| Fujita, M | 1 |
| Mochizuki, K | 1 |
| Shin, I | 1 |
| Morita, T | 1 |
| Hikita, T | 1 |
| Itakura, H | 1 |
| Takahashi, Y | 1 |
| Mizuno, S | 1 |
| Ohno, Y | 1 |
| Ito, K | 1 |
| Ito, T | 1 |
| Soma, M | 3 |
| Yilmaz, MI | 2 |
| Sonmez, A | 2 |
| Saglam, M | 2 |
| Kurt, YG | 1 |
| Unal, HU | 1 |
| Karaman, M | 1 |
| Gok, M | 1 |
| Cetinkaya, H | 1 |
| Eyileten, T | 2 |
| Oguz, Y | 1 |
| Vural, A | 1 |
| Mallamaci, F | 1 |
| Zoccali, C | 1 |
| Pan, Y | 3 |
| Qiao, QY | 1 |
| Pan, LH | 1 |
| Zhou, DC | 1 |
| Hu, C | 1 |
| Gu, HF | 1 |
| Fu, SK | 1 |
| Liu, XL | 1 |
| Jin, HM | 3 |
| Lee, IT | 1 |
| Sheu, WH | 1 |
| Hung, YJ | 1 |
| Chen, JF | 1 |
| Wang, CY | 1 |
| Lee, WJ | 1 |
| Toto, RD | 3 |
| Tian, M | 1 |
| Fakouhi, K | 1 |
| Champion, A | 1 |
| Bacher, P | 1 |
| Guo, LL | 1 |
| Khan, AH | 1 |
| Sattar, MA | 2 |
| Abdullah, NA | 2 |
| Johns, EJ | 2 |
| Sasaki, H | 1 |
| Saiki, A | 1 |
| Endo, K | 1 |
| Ban, N | 1 |
| Yamaguchi, T | 1 |
| Kawana, H | 1 |
| Nagayama, D | 1 |
| Ohhira, M | 1 |
| Oyama, T | 1 |
| Miyashita, Y | 1 |
| Shirai, K | 1 |
| Khan, MA | 1 |
| Abdulla, MH | 1 |
| Salman, IM | 1 |
| Kazi, RN | 1 |
| Swarup, KR | 1 |
| Rathore, HA | 1 |
| Basri, F | 1 |
| Hussain, NM | 1 |
| Dewa, A | 1 |
| Carrero, JJ | 1 |
| Martín-Ventura, JL | 1 |
| Celik, T | 1 |
| Yaman, H | 1 |
| Yenicesu, M | 1 |
| Moreno, JA | 1 |
| Egido, J | 1 |
| Blanco-Colio, LM | 1 |
| Sepehr-Ara, L | 1 |
| Sepehr-Ara, M | 1 |
| Mahmoudian, M | 1 |
| Abe, M | 2 |
| Okada, K | 2 |
| Maruyama, N | 2 |
| Matsumoto, S | 1 |
| Maruyama, T | 1 |
| Matsumoto, K | 1 |
| Holtkamp, FA | 1 |
| de Zeeuw, D | 1 |
| de Graeff, PA | 1 |
| Laverman, GD | 1 |
| Berl, T | 3 |
| Remuzzi, G | 2 |
| Packham, D | 1 |
| Lewis, JB | 5 |
| Parving, HH | 1 |
| Lambers Heerspink, HJ | 1 |
| Haneda, M | 1 |
| Ito, S | 1 |
| Kashihara, N | 1 |
| Node, K | 1 |
| Nangaku, M | 1 |
| Shimosawa, T | 1 |
| Kishimoto, J | 1 |
| Babazono, T | 1 |
| Kario, K | 1 |
| Hiroo, K | 1 |
| Oda, T | 1 |
| Kushiyama, T | 1 |
| Higashi, K | 1 |
| Yamamoto, K | 1 |
| Rodríguez-Pérez, JC | 1 |
| García-Bello, MA | 1 |
| Anabitarte-Prieto, A | 1 |
| Companioni, O | 1 |
| Nóvoa-Mogollón, FJ | 1 |
| Suárez-Ortega, S | 1 |
| Plaza-Toledano, C | 1 |
| Rodríguez-Esparragón, F | 1 |
| Fujita, H | 1 |
| Fujishima, H | 1 |
| Morii, T | 1 |
| Sakamoto, T | 1 |
| Komatsu, K | 1 |
| Hosoba, M | 1 |
| Narita, T | 1 |
| Takahashi, K | 1 |
| Takahashi, T | 1 |
| Yamada, Y | 1 |
| Evans, M | 1 |
| Bain, SC | 1 |
| Hogan, S | 1 |
| Bilous, RW | 2 |
| Suzuki, H | 2 |
| Fujii, Y | 1 |
| Ito, M | 1 |
| Yoshida, Y | 1 |
| Aritomi, S | 1 |
| Niinuma, K | 1 |
| Ogawa, T | 1 |
| Konda, T | 1 |
| Nitta, K | 1 |
| Matavelli, LC | 1 |
| Siragy, HM | 1 |
| Chen, J | 1 |
| Gu, Y | 1 |
| Lin, F | 1 |
| Yang, H | 1 |
| Zhu, W | 1 |
| Ma, J | 1 |
| Lin, S | 1 |
| Wheeldon, NM | 1 |
| Bernadet-Monrozies, P | 1 |
| Rostaing, L | 1 |
| Kamar, N | 1 |
| Durand, D | 1 |
| Kuriyama, S | 1 |
| Tomonari, H | 1 |
| Tokudome, G | 1 |
| Horiguchi, M | 1 |
| Hayashi, H | 1 |
| Kobayashi, H | 1 |
| Ishikawa, M | 1 |
| Hosoya, T | 1 |
| Davis, BJ | 1 |
| Cao, Z | 2 |
| de Gasparo, M | 1 |
| Kawachi, H | 1 |
| Cooper, ME | 2 |
| Allen, TJ | 2 |
| Hunsicker, LG | 7 |
| Pfeffer, MA | 1 |
| Porush, JG | 1 |
| Rouleau, JL | 1 |
| Drury, PL | 1 |
| Esmatjes, E | 2 |
| Hricik, D | 1 |
| Parikh, CR | 1 |
| Raz, I | 2 |
| Vanhille, P | 1 |
| Wiegmann, TB | 2 |
| Wolfe, BM | 1 |
| Locatelli, F | 2 |
| Goldhaber, SZ | 1 |
| Lewis, EJ | 8 |
| Rodby, RA | 7 |
| Chiou, CF | 1 |
| Borenstein, J | 1 |
| Smitten, A | 1 |
| Sengupta, N | 1 |
| Palmer, AJ | 4 |
| Roze, S | 3 |
| Annemans, L | 3 |
| Simon, TA | 1 |
| Chen, RS | 1 |
| Lamotte, M | 2 |
| Ritz, E | 4 |
| Ruilope, LM | 2 |
| Segura, J | 1 |
| Coyle, D | 1 |
| Lehfeld, LS | 1 |
| Silveira, LA | 1 |
| Ghini, B | 1 |
| Lopes de Faria, JB | 1 |
| Ma, G | 1 |
| Bakris, GL | 2 |
| McCullough, PA | 2 |
| Atkins, RC | 3 |
| Briganti, EM | 1 |
| Braden, G | 1 |
| Champion de Crespigny, PJ | 1 |
| DeFerrari, G | 2 |
| Drury, P | 1 |
| Krimholtz, MJ | 1 |
| Thomas, S | 1 |
| Bilous, R | 1 |
| Pohl, MA | 2 |
| Blumenthal, S | 1 |
| Cordonnier, DJ | 1 |
| De Alvaro, F | 1 |
| Eisner, G | 1 |
| Gilbert, RE | 1 |
| de Faria, JB | 1 |
| Mangili, R | 1 |
| Moore, J | 1 |
| Reisin, E | 1 |
| Schernthaner, G | 1 |
| Spitalewitz, S | 1 |
| Tindall, H | 1 |
| Friedman, AN | 1 |
| Selhub, J | 1 |
| Bostom, AG | 1 |
| Bertoluci, MC | 1 |
| Uebel, D | 1 |
| Schmidt, A | 1 |
| Thomazelli, FC | 1 |
| Oliveira, FR | 1 |
| Schmid, H | 1 |
| Frei, A | 1 |
| Burnier, M | 1 |
| Hess, B | 1 |
| Thornley-Brown, D | 1 |
| Wang, X | 1 |
| Wright, JT | 1 |
| Randall, OS | 1 |
| Miller, ER | 1 |
| Lash, JP | 1 |
| Gassman, J | 1 |
| Contreras, G | 1 |
| Appel, LJ | 1 |
| Agodoa, LY | 1 |
| Cheek, D | 1 |
| Ruggenenti, P | 1 |
| Wang, JG | 1 |
| Li, Y | 1 |
| Franklin, SS | 1 |
| Safar, M | 1 |
| Bönner, G | 1 |
| Rocha, R | 1 |
| Purkayastha, D | 1 |
| Davis, P | 1 |
| Busch, M | 1 |
| Franke, S | 1 |
| Wolf, G | 1 |
| Rohde, RD | 2 |
| Stein, G | 1 |
| Velussi, M | 1 |
| Brocco, E | 1 |
| Frigato, F | 1 |
| Zolli, M | 1 |
| Muollo, B | 1 |
| Maioli, M | 1 |
| Carraro, A | 1 |
| Tonolo, G | 1 |
| Fresu, P | 1 |
| Cernigoi, AM | 1 |
| Fioretto, P | 1 |
| Nosadini, R | 1 |
| Clarke, WR | 2 |
| Anzalone, DA | 1 |
| Shigihara, T | 1 |
| Sato, A | 1 |
| Hayashi, K | 1 |
| Saruta, T | 1 |
| Satomura, A | 1 |
| Hidaka, M | 1 |
| Ohsawa, I | 1 |
| Endo, M | 1 |
| Ohi, H | 1 |
| Rohde, R | 1 |
| Studney, D | 1 |
| Taniguchi, M | 1 |
| Kim, S | 1 |
| Zhan, Y | 1 |
| Iwao, H | 1 |
| Os, I | 1 |
| Stenehjem, A | 1 |
| Høieggen, A | 1 |
| Draganov, B | 1 |
| Jenssen, T | 1 |
| Holdaas, H | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Pediatric Hypertension and the Renin-Angiotensin SystEm (PHRASE): The Role of Angiotensin-(1-7) in Hypertension and Hypertension-Induced Heart and Kidney Damage[NCT04752293] | 125 participants (Anticipated) | Observational | 2021-05-19 | Recruiting | |||
| A 24-week Study to Evaluate the Effectiveness of Valsartan in Combination With Hydrochlorothiazide Versus Amlodipine on Arterial Compliance in Patients With Hypertension, Type 2 Diabetes and Albuminuria[NCT00171561] | Phase 4 | 144 participants (Actual) | Interventional | 2003-03-31 | Completed | ||
| Evaluation of Hematologic Patients - Training Protocol[NCT00001715] | 898 participants (Actual) | Observational | 1998-04-21 | Completed | |||
| [NCT01738945] | Phase 4 | 32 participants (Actual) | Interventional | 2008-02-29 | Completed | ||
| Adiponectin is Positively Associated With Insulin Resistance in Subjects With Type 2 Diabetic Nephropathy and Effects by Angiotensin Type 1 Receptor Blocker Losartan[NCT00774904] | 80 participants (Actual) | Interventional | 2007-04-30 | Completed | |||
| The Effects of Renin Angiotensin System Blockage (RAS), Calcium Channel Blocker and Combine Drugs on TWEAK, PTX3 and FMD Levels in Diabetic Proteinuric Patients With Hypertension[NCT00921570] | Phase 4 | 105 participants (Actual) | Interventional | 2008-02-29 | Completed | ||
| Medication Adherence Given Individual SystemCHANGE(TM) in Advancing Nephropathy (MAGICIAN) Pilot Study[NCT04616612] | 150 participants (Anticipated) | Interventional | 2021-12-15 | Recruiting | |||
| [NCT00021918] | 0 participants | Observational | 2001-04-30 | Completed | |||
| Open, Randomized, Unicenter Study Comparing Metabolic Surgery With Intensive Medical Therapy to Treat Diabetic Kidney Disease[NCT04626323] | Phase 2 | 60 participants (Anticipated) | Interventional | 2021-05-25 | Recruiting | ||
| Determinants of Diabetic Nephropathy in American Indians[NCT01878045] | 141 participants (Actual) | Observational | 2013-11-07 | Suspended (stopped due to This study is on a temporary Administrative Hold pending further discussion for NIDDK and Tribal Leadership.) | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
10 reviews available for amlodipine and Diabetic Glomerulosclerosis
| Article | Year |
|---|---|
Amlodipine in the Era of New Generation Calcium Channel Blockers.
Topics: Albuminuria; Amlodipine; Atherosclerosis; Calcium Channel Blockers; Diabetes Complications; Diabetic | 2018 |
Albuminuria and blood pressure, independent targets for cardioprotective therapy in patients with diabetes and nephropathy: a post hoc analysis of the combined RENAAL and IDNT trials.
Topics: Aged; Albuminuria; Amlodipine; Angiotensin Receptor Antagonists; Biphenyl Compounds; Blood Pressure; | 2011 |
[Large scale clinical trials in prevention of end-stage renal disease due to type 2 diabetes with angiotensin receptor antagonists].
Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Clinical Trials as Topic; | 2002 |
[The effect of angiotensin-converting enzyme inhibitors on the progression of chronic renal failure].
Topics: Amlodipine; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibito | 2002 |
Treatment of diabetic nephropathy with angiotensin II receptor antagonist.
Topics: Amlodipine; Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compounds; Creatinin | 2003 |
Losartan and other angiotensin II antagonists for nephropathy in type 2 diabetes mellitus: a review of the clinical trial evidence.
Topics: Albuminuria; Amlodipine; Angiotensin II; Antihypertensive Agents; Biphenyl Compounds; Clinical Trial | 2003 |
Prevention of stroke and myocardial infarction by amlodipine and Angiotensin receptor blockers: a quantitative overview.
Topics: Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Coronary Artery | 2007 |
Renoprotection and renin-angiotensin system blockade in diabetes mellitus.
Topics: Amlodipine; Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compounds; Diabetic | 1997 |
Angiotensin blockade in type 2 diabetes: what the new evidence tells us about renal and cardiac complications.
Topics: Albuminuria; Amlodipine; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; | 2002 |
[Type 2 diabetes and nephropathy--new studies, new treatment strategies?].
Topics: Amlodipine; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Calci | 2002 |
37 trials available for amlodipine and Diabetic Glomerulosclerosis
| Article | Year |
|---|---|
Effect of renin-angiotensin system blockade on soluble Klotho in patients with type 2 diabetes, systolic hypertension, and albuminuria.
Topics: Aged; Albuminuria; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Biomarkers; Blood Pressure; | 2013 |
Effect of renin-angiotensin system blockade on soluble Klotho in patients with type 2 diabetes, systolic hypertension, and albuminuria.
Topics: Aged; Albuminuria; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Biomarkers; Blood Pressure; | 2013 |
Effect of renin-angiotensin system blockade on soluble Klotho in patients with type 2 diabetes, systolic hypertension, and albuminuria.
Topics: Aged; Albuminuria; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Biomarkers; Blood Pressure; | 2013 |
Effect of renin-angiotensin system blockade on soluble Klotho in patients with type 2 diabetes, systolic hypertension, and albuminuria.
Topics: Aged; Albuminuria; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Biomarkers; Blood Pressure; | 2013 |
Effect of renin-angiotensin system blockade on soluble Klotho in patients with type 2 diabetes, systolic hypertension, and albuminuria.
Topics: Aged; Albuminuria; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Biomarkers; Blood Pressure; | 2013 |
Effect of renin-angiotensin system blockade on soluble Klotho in patients with type 2 diabetes, systolic hypertension, and albuminuria.
Topics: Aged; Albuminuria; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Biomarkers; Blood Pressure; | 2013 |
Effect of renin-angiotensin system blockade on soluble Klotho in patients with type 2 diabetes, systolic hypertension, and albuminuria.
Topics: Aged; Albuminuria; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Biomarkers; Blood Pressure; | 2013 |
Effect of renin-angiotensin system blockade on soluble Klotho in patients with type 2 diabetes, systolic hypertension, and albuminuria.
Topics: Aged; Albuminuria; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Biomarkers; Blood Pressure; | 2013 |
Effect of renin-angiotensin system blockade on soluble Klotho in patients with type 2 diabetes, systolic hypertension, and albuminuria.
Topics: Aged; Albuminuria; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Biomarkers; Blood Pressure; | 2013 |
Comparison of the antialbuminuric effects of L-/N-type and L-type calcium channel blockers in hypertensive patients with diabetes and microalbuminuria: the study of assessment for kidney function by urinary microalbumin in randomized (SAKURA) trial.
Topics: Aged; Albuminuria; Amlodipine; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Ca | 2013 |
The effects of calcium channel blockers on nephropathy and pigment epithelium-derived factor in the treatment of hypertensive patients with type 2 diabetes mellitus.
Topics: Aged; Albuminuria; Amlodipine; Blood Pressure; Calcium Channel Blockers; Creatinine; Diabetes Mellit | 2015 |
Effects of the N/L-type calcium channel blocker cilnidipine on nephropathy and uric acid metabolism in hypertensive patients with chronic kidney disease (J-CIRCLE study).
Topics: Aged; Aged, 80 and over; Albuminuria; Amlodipine; Blood Pressure; Calcium Channel Blockers; Creatini | 2014 |
Ramipril lowers plasma FGF-23 in patients with diabetic nephropathy.
Topics: Adult; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Diabetes Mellitus, Type | 2014 |
Losartan reduces insulin resistance by inhibiting oxidative stress and enhancing insulin signaling transduction.
Topics: 3T3-L1 Cells; Adipocytes; Aged; Amlodipine; Animals; Antihypertensive Agents; Diabetic Nephropathies | 2015 |
Assessment of glomerular filtration rate based on alterations of serum brain-derived neurotrophic factor in type 2 diabetic subjects treated with amlodipine/benazepril or valsartan/hydrochlorothiazide.
Topics: Aged; Amlodipine; Antihypertensive Agents; Benzazepines; Brain-Derived Neurotrophic Factor; Diabetes | 2015 |
Effects of calcium channel blockers on proteinuria in patients with diabetic nephropathy.
Topics: Aged; Albuminuria; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Be | 2008 |
Adiponectin is positively associated with insulin resistance in subjects with type 2 diabetic nephropathy and effects of angiotensin II type 1 receptor blocker losartan.
Topics: Adiponectin; Adult; Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Blood Pressure; Diabe | 2009 |
Protective effects of efonidipine, a T- and L-type calcium channel blocker, on renal function and arterial stiffness in type 2 diabetic patients with hypertension and nephropathy.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Aged; Aldosterone; Amlodipine; Arteries; Calcium Channel Blockers; Calc | 2009 |
Combined therapy with renin-angiotensin system and calcium channel blockers in type 2 diabetic hypertensive patients with proteinuria: effects on soluble TWEAK, PTX3, and flow-mediated dilation.
Topics: Adult; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; C-Reactive Prot | 2010 |
Benidipine reduces albuminuria and plasma aldosterone in mild-to-moderate stage chronic kidney disease with albuminuria.
Topics: Aged; Albuminuria; Aldosterone; Amlodipine; Angiotensin Receptor Antagonists; Blood Pressure; Calciu | 2011 |
Design and rationale of Japanese evaluation between Formula of Azelnidipine and amlodipine add on olmesartan to Get antialbuminuric effect study (J-FLAG) : evaluation of the antialbuminuric effects between calcium channel blocker with sympatholytic action
Topics: Adult; Aged; Albuminuria; Amlodipine; Azetidinecarboxylic Acid; Calcium Channel Blockers; Diabetic N | 2011 |
Design and rationale of the study of assessment for kidney function by urinary microalbumin in randomized (SAKURA) trial.
Topics: Aged; Albuminuria; Amlodipine; Calcium Channel Blockers; Calcium Channels, L-Type; Calcium Channels, | 2011 |
[The Shiga Microalbuminuria Reduction Trial].
Topics: Albuminuria; Amlodipine; Animals; Antihypertensive Agents; Diabetes Mellitus, Type 2; Diabetic Nephr | 2010 |
Anti-albuminuric effects of the angiotensin AT1 receptor blocker telmisartan in hypertensive patients.
Topics: Adult; Aged; Aged, 80 and over; Albuminuria; Amlodipine; Angiotensin II Type 1 Receptor Blockers; An | 2011 |
Additive renoprotective effects of aliskiren on angiotensin receptor blocker and calcium channel blocker treatments for type 2 diabetic patients with albuminuria.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Adult; Aged; Albuminuria; Aldosterone; Amides; Amlodipine; Angiotensin | 2012 |
Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect.
Topics: Adult; Aged; Albuminuria; Amlodipine; Angiotensin Receptor Antagonists; Antihypertensive Agents; Blo | 2002 |
Antiproteinuric effects of combined antihypertensive therapies in patients with overt type 2 diabetic nephropathy.
Topics: Aged; Amlodipine; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihy | 2002 |
Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy.
Topics: Amlodipine; Angiotensin II; Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Comp | 2003 |
An economic evaluation of the Irbesartan in Diabetic Nephropathy Trial (IDNT) in a UK setting.
Topics: Amlodipine; Antihypertensive Agents; Biphenyl Compounds; Cohort Studies; Cost-Benefit Analysis; Diab | 2004 |
Rationale and design of a study comparing two fixed-dose combination regimens to reduce albuminuria in patients with type II diabetes and hypertension.
Topics: Adult; Aged; Aged, 80 and over; Albuminuria; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; A | 2005 |
Proteinuria reduction and progression to renal failure in patients with type 2 diabetes mellitus and overt nephropathy.
Topics: Adult; Aged; Amlodipine; Biphenyl Compounds; Blood Pressure; Diabetes Mellitus, Type 2; Diabetic Nep | 2005 |
Targeting albumin excretion rate in the treatment of the hypertensive diabetic patient with renal disease.
Topics: Adult; Aged; Albuminuria; Amlodipine; Benzimidazoles; Biphenyl Compounds; Cross-Over Studies; Diabet | 2005 |
Independent and additive impact of blood pressure control and angiotensin II receptor blockade on renal outcomes in the irbesartan diabetic nephropathy trial: clinical implications and limitations.
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Biphenyl Compounds; Di | 2005 |
Total plasma homocysteine and arteriosclerotic outcomes in type 2 diabetes with nephropathy.
Topics: Aged; Amlodipine; Antihypertensive Agents; Arteriosclerosis; Biphenyl Compounds; Cardiovascular Syst | 2005 |
Urinary TGF-beta1 reduction related to a decrease of systolic blood pressure in patients with type 2 diabetes and clinical diabetic nephropathy.
Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Atenolol; Blood Gluco | 2006 |
Angiotensin type-1 receptor blockade with losartan increases insulin sensitivity and improves glucose homeostasis in subjects with type 2 diabetes and nephropathy.
Topics: Adult; Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Blood Glucose; C-Peptide; Calcium | 2007 |
Effects of different ACE inhibitor combinations on albuminuria: results of the GUARD study.
Topics: Adult; Aged; Aged, 80 and over; Albuminuria; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; A | 2008 |
Serum levels of the advanced glycation end products Nepsilon-carboxymethyllysine and pentosidine are not influenced by treatment with the angiotensin receptor II type 1 blocker irbesartan in patients with type 2 diabetic nephropathy and hypertension.
Topics: Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Arginine; Biphen | 2008 |
Effects of cilazapril and amlodipine on kidney function in hypertensive NIDDM patients.
Topics: Adult; Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pr | 1996 |
Renoprotection and renin-angiotensin system blockade in diabetes mellitus.
Topics: Amlodipine; Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compounds; Diabetic | 1997 |
The Irbesartan type II diabetic nephropathy trial: study design and baseline patient characteristics. For the Collaborative Study Group.
Topics: Adult; Aged; Amlodipine; Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compoun | 2000 |
Effect of combination therapy of angiotensin-converting enzyme inhibitor plus calcium channel blocker on urinary albumin excretion in hypertensive microalbuminuric patients with type II diabetes.
Topics: Aged; Albuminuria; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Calcium Cha | 2000 |
Angiotensin-converting enzyme inhibitors improve nephrosis more quickly than calcium antagonists in diabetic patients.
Topics: Adult; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Calcium Channel Blocker | 2000 |
Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes.
Topics: Adult; Aged; Amlodipine; Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compoun | 2001 |
Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes.
Topics: Adult; Aged; Amlodipine; Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compoun | 2001 |
Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes.
Topics: Adult; Aged; Amlodipine; Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compoun | 2001 |
Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes.
Topics: Adult; Aged; Amlodipine; Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compoun | 2001 |
A clinical trial in type 2 diabetic nephropathy.
Topics: Adult; Aged; Amlodipine; Angiotensin Receptor Antagonists; Biphenyl Compounds; Calcium Channel Block | 2001 |
25 other studies available for amlodipine and Diabetic Glomerulosclerosis
| Article | Year |
|---|---|
Effects of Valsartan and Amlodipine Tablets Combined with α-Lipoic Acid on T-AOC, IL-6 and β2-MG Levels in Patients with Diabetic Nephropathy.
Topics: Amlodipine; Antihypertensive Agents; Antioxidants; Diabetes Mellitus, Type 2; Diabetic Nephropathies | 2023 |
Successful re-administration of Pazopanib in a patient with metastatic renal cell carcinoma and a history of Pazopanib-induced nephrotic syndrome: a case report.
Topics: Aged; Amlodipine; Angiogenesis Inhibitors; Antihypertensive Agents; Antineoplastic Agents; Carcinoma | 2019 |
Effect of calcium channel blockade on adrenergically induced renal vasoconstriction in rat models of renal impairment.
Topics: Amlodipine; Animals; Calcium Channel Blockers; Diabetic Nephropathies; Disease Models, Animal; Drug | 2009 |
Functional subtypes of renal alpha1-adrenoceptor in spontaneously hypertensive rats with streptozotocin-induced experimental diabetic nephropathy.
Topics: Adrenergic Antagonists; Amlodipine; Animals; Diabetes Mellitus, Experimental; Diabetic Nephropathies | 2009 |
Effect of the two new calcium channel blockers mebudipine and dibudipine in comparison to amlodipine on vascular flow of isolated kidney of diabetic rat.
Topics: Amlodipine; Animals; Blood Pressure; Calcium Channel Blockers; Diabetes Mellitus, Experimental; Diab | 2010 |
Modulation of renal superoxide dismutase by telmisartan therapy in C57BL/6-Ins2(Akita) diabetic mice.
Topics: Acetophenones; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents | 2012 |
Irbesartan delays progression of nephropathy as measured by estimated glomerular filtration rate: post hoc analysis of the Irbesartan Diabetic Nephropathy Trial.
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Creatinine; Di | 2012 |
Additive effects of cilnidipine and angiotensin II receptor blocker in preventing the progression of diabetic nephropathy in diabetic spontaneously hypertensive rats.
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Biomarkers; B | 2013 |
Reduction of aldosterone production improves renal oxidative stress and fibrosis in diabetic rats.
Topics: Aldosterone; Amides; Amlodipine; Animals; Antihypertensive Agents; Blood Glucose; Blood Pressure; Cy | 2013 |
Endothelin receptor antagonist combined with a calcium channel blocker attenuates renal injury in spontaneous hypertensive rats with diabetes.
Topics: Amlodipine; Angiotensin II; Animals; Bosentan; Calcium Channel Blockers; Collagen Type IV; Diabetic | 2002 |
Disparate effects of angiotensin II antagonists and calcium channel blockers on albuminuria in experimental diabetes and hypertension: potential role of nephrin.
Topics: Albuminuria; Amlodipine; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Blood P | 2003 |
Summaries for patients. Effects of blood pressure drugs in patients with diabetes and kidney disease.
Topics: Amlodipine; Angiotensin II; Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Comp | 2003 |
The cost-effectiveness of irbesartan in the treatment of hypertensive patients with type 2 diabetic nephropathy.
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Biphenyl Compounds; Cost-Benefit Analysis; Diabete | 2003 |
[Health economic consequences of the use of irbesartan in patients in Germany with type 2 diabetes, nephropathy and hypertension].
Topics: Amlodipine; Antihypertensive Agents; Biphenyl Compounds; Computer Simulation; Creatinine; Diabetes M | 2004 |
Economic evaluation of the use of irbesartan and amlodipine in the treatment of diabetic nephropathy in patients with hypertension in Canada.
Topics: Adult; Aged; Amlodipine; Biphenyl Compounds; Cohort Studies; Cost-Benefit Analysis; Diabetic Nephrop | 2004 |
Early blood pressure normalization independent of the class of antihypertensive agent prevents augmented renal fibronectin and albuminuria in experimental diabetic nephropathy.
Topics: Albuminuria; Amlodipine; Animals; Antihypertensive Agents; Blood Glucose; Blood Pressure; Body Weigh | 2004 |
Calcium channel blockers, either amlodipine or mibefradil, ameliorate renal injury in experimental diabetes.
Topics: Albuminuria; Amlodipine; Animals; Azo Compounds; Blood Pressure; Calcium Channel Blockers; Collagen | 2004 |
[Type 2 diabetic patient with kidney damage. Sartans banish dialysis risk].
Topics: Albuminuria; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Calcium Channel Blockers; Diabetes | 2004 |
[Health economic consequences of the use of irbesartan in patients with type 2 diabetes, hypertension and nephropathy in Switzerland].
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Biphenyl Compounds; Ca | 2006 |
Differing effects of antihypertensive drugs on the incidence of diabetes mellitus among patients with hypertensive kidney disease.
Topics: Adrenergic beta-Antagonists; Adult; Amlodipine; Antihypertensive Agents; Black or African American; | 2006 |
What blood-pressure level provides greatest renoprotection in patients with diabetic nephropathy and hypertension?
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Biphenyl Compounds; Di | 2006 |
[Hypertension therapy for type 2 diabetics].
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antih | 2007 |
[Risk oriented therapy of hypertension. Lowering blood pressure and risk].
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; Cardio | 2007 |
[Diabetic patient with hypertension takes A-I I blocker. Less likely dialysis].
Topics: Albuminuria; Amlodipine; Angiotensin II; Angiotensin Receptor Antagonists; Antihypertensive Agents; | 2002 |
Role of intrarenal angiotensin-converting enzyme in nephropathy of type II diabetic rats.
Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Blood Pressu | 2002 |